Comment on ‘Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab’
Open Access
- 12 July 2020
- journal article
- letter
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 81 (8), e136
- https://doi.org/10.1136/annrheumdis-2020-218365
Abstract
No abstract availableKeywords
Funding Information
- F Hoffmann-La Roche
This publication has 4 references indexed in Scilit:
- Effect of disease duration and other characteristics on efficacy outcomes in clinical trials of tocilizumab for rheumatoid arthritisRheumatology, 2020
- FRI0546 GENDER DIFFERENCES OF RHEUMATIC DISEASES IN MEXICAN POPULATION: DATA FROM THE MEXICAN BIOLOGICS REGISTRYAnnals Of The Rheumatic Diseases, 2020
- Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumabAnnals Of The Rheumatic Diseases, 2020
- Relationship Between Baseline and Early Changes in C‐Reactive Protein and Interleukin‐6 Levels and Clinical Response to Tocilizumab in Rheumatoid ArthritisArthritis Care & Research, 2016